Screener
Crinetics Pharmaceuticals CRNX Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue | 1,271 | 1,235 |
| Operating lease liabilities | 6,536 | 6,489 |
| Total current liabilities | 71,086 | 85,072 |
| Operating lease liabilities, non-current | 41,319 | 42,052 |
| Deferred revenue, non-current | 3,346 | 3,810 |
| Other liabilities | 4,926 | 3,240 |
| TOTAL LIABILITIES | 120,677 | 134,174 |
| Commitments and contingencies (Note 6) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's operating lease liabilities?
- Crinetics Pharmaceuticals (CRNX) reported operating lease liabilities of $41.32M in Q1 2026.
- How has Crinetics Pharmaceuticals's operating lease liabilities changed year-over-year?
- Crinetics Pharmaceuticals's operating lease liabilities decreased by 6.0% year-over-year, from $43.94M to $41.32M.
- What is the long-term trend for Crinetics Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's operating lease liabilities has grown at a 60.0% compound annual growth rate (CAGR), from $4.01M to $42.05M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Crinetics Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude